These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 21566577)

  • 1. Fisetin: a natural fist against melanoma?
    Arbiser JL; Fisher DE
    J Invest Dermatol; 2011 Jun; 131(6):1187-9. PubMed ID: 21566577
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The new arms race against melanoma.
    Lejeune FJ
    Melanoma Res; 2006 Feb; 16(1):1-2. PubMed ID: 16432449
    [No Abstract]   [Full Text] [Related]  

  • 3. Inhibition of human melanoma cell growth by the dietary flavonoid fisetin is associated with disruption of Wnt/β-catenin signaling and decreased Mitf levels.
    Syed DN; Afaq F; Maddodi N; Johnson JJ; Sarfaraz S; Ahmad A; Setaluri V; Mukhtar H
    J Invest Dermatol; 2011 Jun; 131(6):1291-9. PubMed ID: 21346776
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BRAF inhibitors and melanoma.
    Flaherty KT
    Cancer J; 2011; 17(6):505-11. PubMed ID: 22157295
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The brothers RAF.
    Kwong LN; Chin L
    Cell; 2010 Jan; 140(2):180-2. PubMed ID: 20141832
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting BRAF in melanoma: biological and clinical challenges.
    Mandalà M; Voit C
    Crit Rev Oncol Hematol; 2013 Sep; 87(3):239-55. PubMed ID: 23415641
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BRAF in melanoma: current strategies and future directions.
    Salama AK; Flaherty KT
    Clin Cancer Res; 2013 Aug; 19(16):4326-34. PubMed ID: 23770823
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oncogenetics of melanoma: basis for molecular diagnostics and therapy.
    Held L; Eigentler TK; Meier F; Held M; Röcken M; Garbe C; Bauer J
    J Dtsch Dermatol Ges; 2011 Jul; 9(7):510-6. PubMed ID: 21244632
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BRAF, a target in melanoma: implications for solid tumor drug development.
    Flaherty KT; McArthur G
    Cancer; 2010 Nov; 116(21):4902-13. PubMed ID: 20629085
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted therapy for melanoma: rational combinatorial approaches.
    Kwong LN; Davies MA
    Oncogene; 2014 Jan; 33(1):1-9. PubMed ID: 23416974
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting metastatic melanoma.
    Flaherty KT
    Annu Rev Med; 2012; 63():171-83. PubMed ID: 22034865
    [TBL] [Abstract][Full Text] [Related]  

  • 12. On or off target: mutations, models, and predictions.
    Garraway LA; Hahn WC
    Sci Transl Med; 2010 Jun; 2(35):35ps28. PubMed ID: 20538617
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Narrative review: BRAF opens the door for therapeutic advances in melanoma.
    Flaherty KT
    Ann Intern Med; 2010 Nov; 153(9):587-91. PubMed ID: 21041578
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antitumor activity of the selective pan-RAF inhibitor TAK-632 in BRAF inhibitor-resistant melanoma.
    Nakamura A; Arita T; Tsuchiya S; Donelan J; Chouitar J; Carideo E; Galvin K; Okaniwa M; Ishikawa T; Yoshida S
    Cancer Res; 2013 Dec; 73(23):7043-55. PubMed ID: 24121489
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New developments in the treatment of metastatic melanoma: immune checkpoint inhibitors and targeted therapies.
    Azijli K; Stelloo E; Peters GJ; VAN DEN Eertwegh AJ
    Anticancer Res; 2014 Apr; 34(4):1493-505. PubMed ID: 24692676
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatocyte growth factor in the neighborhood reverses resistance to BRAF inhibitor in melanoma.
    Nickoloff BJ; Vande Woude G
    Pigment Cell Melanoma Res; 2012 Nov; 25(6):758-61. PubMed ID: 22974232
    [No Abstract]   [Full Text] [Related]  

  • 17. BRAF inhibitors for the treatment of metastatic melanoma: clinical trials and mechanisms of resistance.
    Alcalá AM; Flaherty KT
    Clin Cancer Res; 2012 Jan; 18(1):33-9. PubMed ID: 22215904
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of the MEK inhibitor trametinib in the treatment of metastatic melanoma.
    King JW; Nathan PD
    Future Oncol; 2014; 10(9):1559-70. PubMed ID: 25145427
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination of RAF and MEK inhibition for the treatment of BRAF-mutated melanoma: feedback is not encouraged.
    Chapman PB; Solit DB; Rosen N
    Cancer Cell; 2014 Nov; 26(5):603-4. PubMed ID: 25517746
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cancer research. Melanoma drug vindicates targeted approach.
    Garber K
    Science; 2009 Dec; 326(5960):1619. PubMed ID: 20019269
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.